Clinical trials
Alzheimer Disease or Associated Disorder clinical trials
Below are recruiting alzheimer disease or associated disorder clinical trials, each written for real people, not researchers. We’re tracking 1,805 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06996730RecruitingPhase 2/Phase 3
Study of donanemab and RG6289 for genetic Alzheimer's disease
This trial tests two medications (donanemab and RG6289) alone or together in people who carry a specific genetic mutation (PSEN1 E280A) that causes early-onset Alzheimer's disease. It aims to see if these drugs can slow or prevent memory loss.
Medellín, AntioquiaAges 25–65 - NCT06639282RecruitingPhase 2
Testing siponimod for mild Alzheimer's dementia
This study tests if a medicine called siponimod, already used for multiple sclerosis, can help people with mild Alzheimer's dementia. You will take a pill daily and be monitored closely for safety and cognitive changes.
Phoenix, ArizonaAges 50–85 - NCT05847192Recruiting
Testing brain-signal networks in Alzheimer’s with hallucinations
This study looks at “tau” (a brain protein) and brain-signal patterns in people with Alzheimer’s disease who have psychotic symptoms like hallucinations or delusions. It may help researchers understand what’s happening in the brain and how to better target these symptoms.
Manhasset, New YorkAges 65–85 - NCT04460872RecruitingPhase 2
Testosterone plus walking training to support bones and muscles
This Phase 2 study tests whether testosterone therapy combined with walking training can improve bone and muscle health after a spinal cord injury. It aims to help men with low testosterone and walking problems by improving strength, body composition, and related health markers.
Gainesville, FloridaAges 18 years+ - NCT07604896RecruitingPhase 4
Lecanemab for early Alzheimer's disease with amyloid buildup
This trial tests lecanemab, an infusion medicine that targets amyloid protein buildup in the brain, in people with mild cognitive impairment or mild Alzheimer's disease. Researchers will track how well it works and study how it affects your body's proteins using advanced lab tests.
Wenzhou, ZhejiangAges 50–90 - NCT07167966Enrolling by invitationPhase 2
Alzheimer's tau vaccine study (AADvac1)
This trial tests a vaccine that targets tau tangles in the brain, which are linked to Alzheimer's. It is part of a larger platform study that combines different experimental treatments.
San Francisco, CaliforniaAges 50–80 - NCT07142278RecruitingPhase 1
Alzheimer's vaccine study for healthy adults ages 40 to 65
This trial tests an experimental vaccine (DUVAX) that targets two proteins linked to Alzheimer's disease: amyloid-beta and tau. It is an early-stage study to check safety and see how the body responds, aiming to prevent or delay the disease.
Miami Lakes, FloridaAges 40–65 - NCT06986447Enrolling by invitation
Non-invasive tests for serious liver disease
This study is testing whether advanced imaging and other non-invasive methods can properly identify people with significant liver scarring due to metabolic liver disease or alcohol-related liver disease. It may help find better ways to track liver health without repeated needle biopsies.
Chandler, ArizonaAges 18–80 - NCT06957418RecruitingPhase 2
Alzheimer's tau drug study for early stage patients
This trial tests a treatment targeting tau protein buildup in the brain for people with early Alzheimer's. You may join if you have memory or thinking changes but are still living independently, and brain scans show both amyloid and tau clumps.
San Francisco, CaliforniaAges 50–80 - NCT06993142Recruiting
Slowing Parkinson's Early With Exercise
This trial tests whether a specific exercise program can slow the early stages of Parkinson's disease in people who have a genetic risk (LRRK2 or GBA variants). You will use a smartphone app to guide your exercise from home.
Rochester, New YorkAges 50 years+ - NCT06058234Recruiting
Tracking Alzheimer’s treatment for Medicare patients in early stages
This study tracks how well a certain type of Alzheimer’s treatment works for people on Medicare who are in the early stages of the disease. The goal is to collect real-world information about the drug’s benefits and risks.
Baltimore, MarylandAges Any age - NCT07768579Recruiting
Sequential treatment for Alzheimer's disease
This study tests a sequence of treatments to see if they can help people with Alzheimer's disease or mild cognitive impairment. It aims to slow down memory decline and improve daily function.
Beijing, Beijing MunicipalityAges 55–85 - NCT07672977Enrolling by invitation
Sound therapy at home to improve deep sleep in early Alzheimer's
This study tests whether a wearable device that plays soft sounds during sleep can boost deep sleep brain waves in people with mild memory problems caused by Alzheimer's. It aims to see if this simple, home-based approach can help protect memory and thinking.
Zaragoza, ZaragozaAges 50–75 - NCT07667478Recruiting
Brain stimulation study for early Alzheimer's memory loss
This study tests whether a non-invasive magnetic brain stimulation technique can help improve memory in people with early Alzheimer's disease. It may be an option if you have mild cognitive impairment or mild dementia due to Alzheimer's and have had a positive blood test for Alzheimer's markers.
Houston, TexasAges 55–90 - NCT07553338RecruitingPhase 2
Leronlimab Safety and Brain Inflammation in Alzheimer's
This study tests whether a drug called leronlimab is safe and can reduce inflammation in the brains of people with mild-to-moderate Alzheimer's disease or memory problems. Researchers will use special brain scans to see if the drug affects inflammation.
New York, New YorkAges 50 years+ - NCT06850597RecruitingPhase 2
Testing dimethyl fumarate for early Alzheimer's disease
This study tests a drug called dimethyl fumarate to see if it can help people with early Alzheimer's disease. It may slow down memory loss and thinking problems.
Lodz, Łódź VoivodeshipAges 55–90 - NCT07221344RecruitingPhase 1/Phase 2
Study of an experimental drug for early Alzheimer's disease
This trial tests an experimental drug, ARO-MAPT-SC, which may slow the progression of early Alzheimer's disease by targeting a protein involved in the disease. It is given as an injection under the skin and is being studied in healthy people and those with early Alzheimer's.
East York, OntarioAges 18–80 - NCT07158905RecruitingPhase 1
Tau vaccine study for early Alzheimer's prevention
This study tests a vaccine that targets tau protein, which is linked to Alzheimer's disease. It is for older adults who have no memory problems yet but have biological signs of early Alzheimer's, to see if the vaccine can prevent or slow down the disease.
Boca Raton, FloridaAges 65–80 - NCT07089303Recruiting
Alzheimer's brain imaging study (AD-MINER)
This study uses advanced brain imaging to learn more about Alzheimer's disease. It looks at people with normal memory, mild memory problems, or Alzheimer's dementia to find better ways to diagnose and track the disease.
Beijing, Beijing MunicipalityAges 55–90 - NCT07036328Recruiting
Magnetic brain stimulation to slow memory loss in Alzheimer's
This study tests whether a noninvasive magnetic brain stimulation treatment can slow down cognitive decline in people with early Alzheimer's disease. You'll receive daily sessions over several weeks, and the goal is to see if it helps preserve memory and thinking skills.
AmsterdamAges 50–85 - NCT07027072RecruitingPhase 2
Testing KDS2010 for early Alzheimer's memory loss
This study tests a new drug called KDS2010 for people with early Alzheimer's or mild memory loss. It aims to see if the drug can slow thinking and memory decline. You will need a caregiver to help with visits and must have a special brain scan showing amyloid plaques.
Gwangju, GwangjuAges 50–85 - NCT06936514Enrolling by invitation
Lymphatic surgery for Alzheimer's: a clinical study
This trial tests a surgery that targets the lymphatic system in the neck to help people with moderate-to-severe Alzheimer's disease. The goal is to see if it can improve cognitive function.
TianjinAges 50–80 - NCT06922188Recruiting
Screening for financial hardship in Alzheimer's and dementia
This study aims to develop a way to measure financial hardship in people with Alzheimer's disease, related dementias, and their caregivers. By taking part, you can help create a tool that may identify financial struggles and connect families with needed support.
Seattle, WashingtonAges 18 years+ - NCT06891443RecruitingPhase 3
Study of Sepofarsen for LCA type 10
This study tests an investigational RNA therapy called sepofarsen for people with Leber Congenital Amaurosis (LCA) type 10, a rare inherited eye disease that causes severe vision loss from birth. The goal is to see if it can slow or improve vision loss.
San Francisco, CaliforniaAges 6 years+
Hear when a new Alzheimer Disease or Associated Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for alzheimer disease or associated disorder?
- Yes. Clin2 currently lists 1,805 recruiting alzheimer disease or associated disorder studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a alzheimer disease or associated disorder trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a alzheimer disease or associated disorder trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.